Elicio Therapeutics plans Phase 1 trial of ELI-002 7P plus anti-PD-1, chemo in metastatic mKRAS pancreatic cancer

Elicio Therapeutics, Inc

Elicio Therapeutics, Inc

ELTX

0.00
  • Elicio Therapeutics reported preliminary Phase 2 AMPLIFY-7P observations that support testing ELI-002 7P with checkpoint inhibitors in metastatic mKRAS pancreatic cancer.
  • Results have not been presented yet; a virtual key opinion leader event is scheduled for June 24, 2026.
  • Three patients later achieved confirmed complete tumor responses on nivolumab-based therapy, suggesting ELI-002 7P may prime sensitivity to immunotherapy.
  • The company plans a funding-dependent Phase 1 trial in first-line metastatic mKRAS PDAC combining ELI-002 7P, standard chemotherapy, and an anti-PD-1 drug.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170800PRIMZONEFULLFEED9748369) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.